These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16477576)

  • 1. Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
    Cook PP
    Clin Infect Dis; 2006 Mar; 42(6):892; author reply 892-3. PubMed ID: 16477576
    [No Abstract]   [Full Text] [Related]  

  • 2. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
    McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR
    Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From the Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    JAMA; 2002 Dec; 288(23):2967. PubMed ID: 12492097
    [No Abstract]   [Full Text] [Related]  

  • 5. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
    JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
    [No Abstract]   [Full Text] [Related]  

  • 6. Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis.
    Potolidis E; Mantadakis E; Zeniodi MH; Samonis G
    Scand J Infect Dis; 2005; 37(2):155-7. PubMed ID: 15773037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
    Can Commun Dis Rep; 2001 Jul; 27(13):114-6. PubMed ID: 11443837
    [No Abstract]   [Full Text] [Related]  

  • 8. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
    Jasmer RM; Daley CL
    Am J Respir Crit Care Med; 2003 Mar; 167(6):809-10. PubMed ID: 12623855
    [No Abstract]   [Full Text] [Related]  

  • 9. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Aug; 50(34):733-5. PubMed ID: 11787580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
    Ijaz K; McElroy PD; Navin TR
    Clin Infect Dis; 2004 Jul; 39(2):289. PubMed ID: 15307044
    [No Abstract]   [Full Text] [Related]  

  • 11. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.
    Kunimoto D; Warman A; Beckon A; Doering D; Melenka L
    Clin Infect Dis; 2003 Jun; 36(12):e158-61. PubMed ID: 12802781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From the Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
    JAMA; 2001 May 23-30; 285(20):2572-3. PubMed ID: 11396466
    [No Abstract]   [Full Text] [Related]  

  • 13. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Apr; 50(15):289-91. PubMed ID: 11330495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of the rifampin and pyrazinamide short-course regimen for treating latent tuberculosis infection.
    Ijaz K; McElroy PD; Jereb J; Navin TR; Castro KG
    Clin Infect Dis; 2007 Feb; 44(3):464-5; author reply 465. PubMed ID: 17205462
    [No Abstract]   [Full Text] [Related]  

  • 15. Rifampicin/pyrazinamide therapy should not be used for latent tuberculosis infection.
    Garca-Doval I
    J Am Acad Dermatol; 2004 May; 50(5):801; author reply 801-2. PubMed ID: 15097974
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection.
    Ijaz K; Jereb JA; Lambert LA; Bower WA; Spradling PR; McElroy PD; Iademarco MF; Navin TR; Castro KG
    Clin Infect Dis; 2006 Feb; 42(3):346-55. PubMed ID: 16392079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
    Duarte R; Carvalho A; Correia A
    Public Health; 2012 Sep; 126(9):760-2. PubMed ID: 22633080
    [No Abstract]   [Full Text] [Related]  

  • 18. US guidelines for treatment of latent tuberculosis revised.
    McCarthy M
    Lancet; 2001 Sep; 358(9284):816. PubMed ID: 11564495
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
    Stout JE
    Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003.
    ;
    MMWR Morb Mortal Wkly Rep; 2003 Aug; 52(31):735-9. PubMed ID: 12904741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.